Banner - About IDA
IDA is a common condition in the US and worldwide
IDA is a common condition worldwide
IDA is a common type of anemia that occurs when iron levels are insufficient to generate healthy red blood cells.1
Learn more about IDA symptoms and detecting and diagnosing IDA.
Factors that can contribute to IDA
Factors that can contribute to IDA
Factors that can
contribute to IDA
In iron deficiency, depleted iron stores are due to an imbalance between iron uptake and iron utilization. Anemia may not be present initially because of iron recycling from erythrocyte turnover, but the persistence of a negative balance can lead to microcytic and hypochromic anemia.4 Low iron levels can develop due to a variety of factors.
Patients that may be impacted by malabsorption include those who:
- Have undergone intestinal surgery such as gastric bypass
- Have a disease of the intestine
- Take medications that reduce acid in the stomach
Female patients can be impacted by blood loss through abnormal menstrual periods or bleeding fibroids and childbirth. For all patients, however, blood loss may not be obvious as it may occur slowly and internally. Some examples of this are:
- A bleeding ulcer, colon polyp, or colon cancer
- Regular use of NSAIDs
- Urinary tract bleeding
There are certain stages in your patients’ lives where their need for iron increases, for example, pregnancy. During these times, diet alone may not provide these patients the iron their body needs. It is important to distinguish between the two types of iron that people consume: heme and non-heme. Heme iron derives primarily from meat and non-heme iron is sourced from plants. Meat, poultry, and fish are some of the best sources of heme iron. Vegetarian diets may be a good source of non-heme iron if these patients eat the right foods:
- Dried fruits
- Dark green, leafy vegetables
Heme iron is more easily absorbed into the body than non-heme iron, and heme iron is also the better type of iron to replete those systems which are iron deficient.
Important Safety Information
Injectafer® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease.
IMPORTANT SAFETY INFORMATION
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition. In most cases, hypophosphatemia resolved within three months.
Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).
The following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: cardiac disorders: tachycardia; general disorders and administration site conditions: chest discomfort, chills, pyrexia; metabolism and nutrition disorders: hypophosphatemia; musculoskeletal and connective tissue disorders: arthralgia, back pain, hypophosphatemic osteomalacia (rarely reported event); nervous system disorders: syncope; respiratory, thoracic and mediastinal disorders: dyspnea; skin and subcutaneous tissue disorders: angioedema, erythema, pruritus, urticaria.
You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.